Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Johnson ML, Yande S, Aparasu RR, Wanat M, Toale K. Prevalence and factors associated with the use of direct oral anticoagulants and low molecular weight heparins (LMWH) in cancer patients. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S377-8. doi: 10.1016/j.jval.2023.03.2121